Swiss pharmaceutical giant Novartis has agreed to pay an initial sum of $1.1 billion (CHF883 million) to acquire the British start-up Myricx Bio, which is developing antibody-drug conjugates for various types of solid tumours. The agreement also provides for a further payment of up to CHF400 million, subject to the achievement of predefined milestones, the two companies said in separate statements on Monday. Founded in 2019 as a spin-off from Imperial College London and the Francis Crick Institu